You may also like
The Current Place of Aprotinin in the Management of Bleeding
Following its withdrawal in 2007, which is explained in detail in this review, the regulators have now licensed aprotinin for myocardial revascularisation only, which is relatively low-risk for bleeding.
1 min read
Hetastarch Increases the Risk of Bleeding Complications in Patients After Off-Pump Coronary Bypass Surgery: A Randomized Clinical Trial
Hetastarch is an artificial colloid widely used intraoperatively in fluid-replacement regimens. Previous studies have found that the intraoperative administration of hetastarch may increase the risk of postoperative bleeding in patients who undergo coronary artery bypass graft surgery with cardiopulmonary bypass.
1 min read
Most Deaths in Low-Risk Cardiac Surgery Could Be Avoidable
Logistic regression model identified age, previous coronary stent implantation, coronary artery bypass grafting + heart valve surgery, ≥ 2 combined heart valve surgery and hospital-acquired infection as independent predictors of AD.
1 min read